Products

NAMENDA® (memantine hydrochloride) received approval for the treatment of Alzheimer's disease in Europe in 2002 and in the U.S. in 2003. In the U.S., NAMENDA is currently being sold by Forest Laboratories for moderate-to-severe Alzheimer's disease. In Europe, memantine has been marketed by Merz & Co. for a number of indications for several years. For Alzheimer's disease, memantine is now being sold by Merz's European marketing partner H. Lundbeck. Under an exclusive marketing agreement, the company will receive royalty payments by Merz and its marketing partners from sales of memantine for Alzheimer's disease.